Therapy News and Research

RSS

OvaGene's new molecular diagnostics laboratory receives CLIA-certification

OvaGene Oncology Inc., a molecular diagnostics company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, announced today that the company has received Clinical Laboratory Improvement Act (CLIA) certification for their newly constructed state-of-the-art molecular diagnostics laboratory.

20 Sep 2011

Chronic diseases could cost $47 trillion over the next 20 years: Report

A latest report by the World Economic Forum (WEF) suggests that the global economic impact of the five leading chronic diseases -- cancer, diabetes, mental illness, heart disease, and respiratory disease - could reach $47 trillion over the next 20 years.

19 Sep 2011

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Phenex Pharmaceuticals AG announced today the start of a first-in-man Phase I study with its clinical drug candidate Px-102, a synthetic non-steroidal FXR agonist. The volunteers of the first dose level received the drug and showed no signs of discomfort or other adverse effects.

19 Sep 2011

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

19 Sep 2011

Prevalence of diabetes increases 30% over last four years in urban India

The prevalence of diabetes in urban India is accelerating at a rapid rate and now stands at 5.5 percent (just under 20 million people), compared with 4.6 percent in 2007 - equivalent to a 30 percent increase in actual population numbers over the last four years - according to new research by GfK HealthCare's Roper Global Diabetes Group. Moreover, a full 10 percent of these patients have been diagnosed in the past 12 months.

19 Sep 2011

Tarsa reports positive data from OSTORA Phase III ORACAL trial for postmenopausal osteoporosis

Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.

19 Sep 2011

Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that top-line data from part one of a two-part Phase 1 study of SPI-1620 in combination with docetaxel was presented in an oral presentation at the 12th International Conference on Endothelin, held in Cambridge, United Kingdom, from September 11-14, 2011. Part one of the study has been completed, while part two is ongoing.

19 Sep 2011

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.

19 Sep 2011

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

19 Sep 2011

Scuba diving linked to improved PTSD symptoms in veterans with spinal cord injuries

A small group of veterans with spinal cord injuries who underwent a four-day scuba- diving certification saw significant improvement in muscle movement, increased sensitivity to light touch and pinprick on the legs, and large reductions in post-traumatic stress disorder (PTSD) symptoms, according to Johns Hopkins researchers.

19 Sep 2011

HFSA scientific meeting to discuss long-term management care for LVAD patients

The 15th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature a discussion by Laura Coyle, ACNP, on strategies for caring for LVAD patients in an outpatient setting entitled "Long-Term Management: Caring for Patients to Keep Them at Home."

19 Sep 2011

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced that data about hypoparathyroidism will be presented at the 2011 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego, CA, September 16-20, 2011.

19 Sep 2011

Two newer Type 2 diabetes drugs could be linked to increased risk of pancreatic cancer

Two newer drugs used to treat Type 2 diabetes could be linked to a significantly increased risk of developing pancreatitis and pancreatic cancer, and one could also be linked to an increased risk of thyroid cancer, according to a new UCLA study.

19 Sep 2011

Positive data from Tarsa's OSTORA Phase III trial on postmenopausal osteoporosis

Tarsa Therapeutics today presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA-, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.

19 Sep 2011

NPF announces support for three new Parkinson's research projects

The National Parkinson Foundation (NPF) is proud to announce support for three new research projects which fulfill NPF's mission of improving the quality of care in Parkinson's disease.

19 Sep 2011

Humour as effective as medication in treating agitation in dementia, research shows

...

18 Sep 2011

Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC

Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide.

17 Sep 2011

MedPAC 'doc fix' could undermine seniors' care, jeopardize local jobs, and destabilize key health sector

Commenting on an initial outline from the Medicare Payment Advisory Commission (MedPAC) to address the sustainable growth rate formula used to fund physicians, the Alliance for Quality Nursing Home Care said news reports of proposed Medicare cuts of $49 billion over ten years for post-acute care providers -- on top of the many cuts already in effect -- would severely undermine seniors' care, jeopardize local jobs, and further destabilize a key U.S. health sector already reeling from a series of budgetary and regulatory actions.

17 Sep 2011

New insight into how nervous system regulates immunity

Scientists have identified a surprising new role for a new type of T cell in the immune system: some of them can be activated by nerves to make a neurotransmitter (acetylcholine) that blocks inflammation. The discovery of these T cells is novel and suggests that it may be possible to treat inflammation and autoimmune diseases by targeting the nerves and the T cells. The study was published this week in Science.

17 Sep 2011

New diabetes drugs linked to increased risk of pancreatitis and pancreatic cancer

17 Sep 2011

Therapy News and Research

OvaGene's new molecular diagnostics laboratory receives CLIA-certification

Chronic diseases could cost $47 trillion over the next 20 years: Report

Phenex commences Px-102 first-in-man Phase I study for Metabolic Syndrome and NAFLD

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Prevalence of diabetes increases 30% over last four years in urban India

Tarsa reports positive data from OSTORA Phase III ORACAL trial for postmenopausal osteoporosis

Top-line data from Spectrum's SPI-1620 Phase 1 combination study on carcinoma

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Scuba diving linked to improved PTSD symptoms in veterans with spinal cord injuries

HFSA scientific meeting to discuss long-term management care for LVAD patients

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

Two newer Type 2 diabetes drugs could be linked to increased risk of pancreatic cancer

Positive data from Tarsa's OSTORA Phase III trial on postmenopausal osteoporosis

NPF announces support for three new Parkinson's research projects

Humour as effective as medication in treating agitation in dementia, research shows

Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC

MedPAC 'doc fix' could undermine seniors' care, jeopardize local jobs, and destabilize key health sector

New insight into how nervous system regulates immunity

New diabetes drugs linked to increased risk of pancreatitis and pancreatic cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News